This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Evotec Licenses Phase II Insomnia Candidate To Jingxin Pharma For Development In China

HAMBURG, Germany, Oct. 28, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd ("Jingxin Pharma") for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties.

Jingxin Pharma will initiate clinical trials with EVT 201 in China in 2011. All development costs will be borne by Jingxin Pharma. Evotec will have the right to reference clinical data produced by Jingxin Pharma to support potential further development of EVT 201 in other territories.

Mr. Lu Gang, Chairman of the Board and General Manager of Jingxin Pharma, said: "Although certain aspects of insomnia are addressed by current treatments, high unmet medical needs remain for patients suffering from sleep problems. In two Phase II clinical trials Evotec has demonstrated that EVT 201 potentially offers advantages to existing insomnia agents. We are encouraged to further reveal the potential of this programme to the benefit of patients that are not adequately treated."

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, commented: "Jingxin Pharma is an enthusiastic partner keen to develop EVT 201 for China as the major emerging pharmaceutical market. This deal allows finally the further progression of Evotec's insomnia programme and therefore represents an important step in realising the drug candidate's intrinsic value."

About EVT 201

EVT 201 represents a potential "best in class" treatment for insomnia. Evotec has conducted two Phase II trials of EVT 201 in adult and elderly primary insomnia patients. Both trials demonstrated that treatment with EVT 201 produces large improvements in sleep onset and maintenance measures. In the trial in elderly patients EVT 201 was also objectively demonstrated to have a next-day benefit, namely a reduction of daytime sleepiness.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,068.10 -58.02 -0.32%
S&P 500 2,115.69 -5.10 -0.24%
NASDAQ 5,087.4110 -10.5650 -0.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs